Coloplast’s Q3 18 top-line came in better than our expectations but missed the street’s expectations by a whisker. The bottom-line, on the other hand, lagged ours as well as the street’s estimates. Wound care and urology reported a sequential acceleration while chronic care (continence and ostomy), even though delivered another quarter of market-beating growth, wasn’t better sequentially. Factoring in the Q3 numbers, we will make minor tweaks to our estimates, but we d
22 Aug 2018
Strong top-line but slower than expected bottom-line growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong top-line but slower than expected bottom-line growth
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
22 Aug 2018 -
Author:
Kamla Singh -
Pages:
3
Coloplast’s Q3 18 top-line came in better than our expectations but missed the street’s expectations by a whisker. The bottom-line, on the other hand, lagged ours as well as the street’s estimates. Wound care and urology reported a sequential acceleration while chronic care (continence and ostomy), even though delivered another quarter of market-beating growth, wasn’t better sequentially. Factoring in the Q3 numbers, we will make minor tweaks to our estimates, but we d